MENU
WORLDALLERGY.ORG
Facebook: World Allergy Organization
Twitter: World Allergy Organization
LinkedIn: World Allergy Organization
Instagram: World Allergy Organization
Back to Top

Profile of aniti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases